Position in DNLI
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$555,216
+$312,184 QoQ
Shares Held
21,587
+70.5% QoQ
Ownership
0.014%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#145
of 290 holders
Holding Since
Mar 2023
3 quarters on record
Voting authority
Sole 28%
Shared 23%
None 50%
Common Shares in DNLI Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Cerity Partners LLC holds $424,897,823 across 139 Biotechnology names. DNLI ranks #54 (0.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
255,874 | $127,100,291 | |
| 2 | CORT |
Corcept Therapeutics Inc
|
797,119 | $69,309,495 | |
| 3 | HALO |
Halozyme Therapeutics, Inc.
|
343,589 | $26,892,710 | |
| 4 | REGN |
Regeneron Pharmaceuticals, Inc.
|
39,274 | $24,488,909 | |
| 5 | INCY |
Incyte Corp
|
205,071 | $23,246,847 | |
| 6 | EXEL |
Exelixis, Inc.
|
377,130 | $20,519,642 | |
| 7 | JAZZ |
Jazz Pharmaceuticals plc
|
53,534 | $12,900,087 | |
| 8 | RPRX |
Royalty Pharma plc
|
180,772 | $10,135,884 |
All Filings in DNLI
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $555,216 | 21,587 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $243,032 | 12,658 | Shares | Defined | 2026-05-15 | |
| 2023-03-31 | $348,526 | 15,127 | Shares | Sole | 2023-05-11 | |
| No filing history on record for this holder in this stock. | ||||||